HAEMATOLOGICAL CANCER: Idelalisib-targeting PI3K[delta] in patients with B-cell malignancies.
Burger, Jan A.; Okkenhaug, Klaus
[Miscellaneous] Nature Reviews Clinical Oncology. 11(4):184-186, April 2014.

(Format: HTML, PDF)

: Idelalisib, the first PI3K[delta] inhibitor in clinical use, has excellent activity in patients with chronic lymphocytic leukaemia and indolent B-cell lymphomas, heralding a new era of targeted therapy for these types of cancer. Idelalisib intercepts critical communications between B cells and the microenvironment, including B-cell receptor signalling and chemokine networks.

Copyright (C) 2014 Nature Publishing Group